Alliance for Infectious Disease Treatments

Under their agreement, the companies will share development costs and revenues.

The alliance will combine Ace BioSciences's expertise in finding novel infectious disease targets with Genmab's broad antibody development capabilities and preclinical tools to generate and characterize fully human antibodies. Ace BioSciences will provide commercially promising targets, while Genmab will use its antibody technology to create and develop new therapeutics. Genmab creates and develops fully human antibodies for the treatment of disease. Ace BioSciences's focus on infectious diseases is based on a broad biotechnology platform that integrates biology and analytical chemistry. The company's protein interaction technology is used to discover protein targets in a wide range of infectious bacteria and fungi.

"We are very excited by this alliance with Genmab because the company's expertise and proven track record in developing therapeutic antibodies positions Ace BioSciences on a fast track to develop treatments for infectious diseases,” said Ejvind Mortz, Ph.D., CEO of Ace BioSciences.




Related Links:
Genmab
Ace BioSciences